TetraLogic Pharmaceuticals (TLOG) Stock Price, News & Analysis

Company Overview

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0010
• Volume: 900 shs
• Average Volume: 18,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TLOG Stock Analysis - Frequently Asked Questions

How have TLOG shares performed this year?

TetraLogic Pharmaceuticals' stock was trading at $0.0001 at the beginning of the year. Since then, TLOG shares have increased by 100.0% and is now trading at $0.0002.

How do I buy shares of TetraLogic Pharmaceuticals?

Shares of TLOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TetraLogic Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TetraLogic Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Trevena (TRVN), Vaxart (VXRT), Arrowhead Pharmaceuticals (ARWR), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV) and Gilead Sciences (GILD).

Company Calendar

• Today: 8/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:TLOG
• Previous Symbol: NASDAQ:TLOG
• CIK: 1361248
• Web: www.tetralogicpharma.com
• Phone: (610) 889-9900
• Fax: 610-889-9994
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 5.50